{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:30:37Z","timestamp":1789140637170,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2015-03005"],"award-info":[{"award-number":["2015-03005"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013060","name":"Jilin Provincial Health and Family Planning Commission","doi-asserted-by":"publisher","award":["2016J040"],"award-info":[{"award-number":["2016J040"]}],"id":[{"id":"10.13039\/501100013060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671177"],"award-info":[{"award-number":["81671177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102430","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T22:17:44Z","timestamp":1596061064000},"page":"102430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity"],"prefix":"10.1016","volume":"46","author":[{"given":"Meng-Ge","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-3419","authenticated-orcid":false,"given":"Tao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2020.102430_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102430_bib0002","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/NDT.S147360","article-title":"Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations","volume":"13","author":"Han","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.msard.2020.102430_bib0003","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms17030273","article-title":"The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives","volume":"17","author":"Jasiak-Zatonska","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2020.102430_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol. (Zurich, Switzerland)"},{"key":"10.1016\/j.msard.2020.102430_bib0005","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","article-title":"Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2020.102430_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105793","article-title":"Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis","volume":"75","author":"Hou","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2020.102430_bib0007","article-title":"Lower serum interleukin\u201022 and interleukin\u201035 levels are associated with disease status in neuromyelitis optica spectrum disorders","author":"Yang","year":"2019","journal-title":"CNS Neurosci. Therapeut."},{"key":"10.1016\/j.msard.2020.102430_bib0008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fneur.2018.00044","article-title":"Elevated Plasma Chemokines for Eosinophils in Neuromyelitis Optica Spectrum Disorders during Remission","volume":"9","author":"Tong","year":"2018","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2020.102430_bib0009","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1212\/01.WNL.0000148481.80152.BF","article-title":"Activation of humoral immunity and eosinophils in neuromyelitis optica","volume":"63","author":"Correale J","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102430_bib0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2016.03.004","article-title":"Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders","volume":"293","author":"Zhang","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.msard.2020.102430_bib0011","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/eji.201546095","article-title":"A novel IL-23p19\/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice","volume":"46","author":"Wang","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2020.102430_bib0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/cei.12840","article-title":"Interleukin (IL)-39 [IL-23p19\/Epstein-Barr virus-induced 3 (Ebi3)] induces differentiation\/expansion of neutrophils in lupus-prone mice","volume":"186","author":"Wang","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2020.102430_bib0013","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2019.00201","article-title":"The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders","volume":"10","author":"Hausser-Kinzel","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2020.102430_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.msard.2020.102430_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell-B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.msard.2020.102430_bib0016","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1352458512454771","article-title":"Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis","volume":"19","author":"Quan","year":"2013","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102430_bib0017","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00281-014-0424-x","article-title":"B cells in MS and NMO: pathogenesis and therapy","volume":"36","author":"Krumbholz","year":"2014","journal-title":"Semin. Immunopathol."},{"issue":"2","key":"10.1016\/j.msard.2020.102430_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149411","article-title":"B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine\/Chemokines Are Elevated in MOG Antibody Associated Demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.msard.2020.102430_bib0019","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3389\/fimmu.2016.00479","article-title":"Expanding Diversity in Molecular Structures and Functions of the IL-6\/IL-12 Heterodimeric Cytokine Family","volume":"7","author":"Hasegawa","year":"2016","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2020.102430_bib0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1060028018809522","article-title":"Tildrakizumab: A Review of Phase II and III Clinical Trials","volume":"53","author":"Kolli","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.msard.2020.102430_bib0021","first-page":"1","article-title":"Tildrakizumab for the treatment of psoriasis","author":"Sinclair","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.msard.2020.102430_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105841","article-title":"Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis","volume":"75","author":"Xu","year":"2019","journal-title":"Int. Immunopharmacol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:02Z","timestamp":1761900722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"alternative-id":["S2211034820305058"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102430","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102430"}}